Background: Lung cancer remains the leading cause of cancer-related death, largely owing
to the lack of effective treatments. A tumour vascular targeting strategy presents an attractive …

Heterogeneity of lung tumor endothelial cell (TEC) phenotypes across patients, species
(human/mouse), and models (in vivo/in vitro) remains poorly inventoried at the single-cell …

Introduction We aim to describe the molecular mechanisms relevant to angiogenesis
inhibition and to critically evaluate the current evidence for the use of angiogenic inhibitors …

Angiogenesis is a hallmark of solid tumors, and disruption of tumor vasculature is an active
anticancer therapy in some cases. Several proteins expressed on the surface of tumor …

Lung cancer is a highly prevalent disease worldwide. Currently, there are more than 150
million patients with lung cancer in the world, with more than 1 million new cases diagnosed …

Tumor endothelial cells regulate several aspects of tumor biology, from delivering oxygen
and nutrients to shaping the immune response against a tumor and providing a barrier …

In lung cancer, antiangiogenic treatment targeting tumor endothelial cells (ECs) provides a
survival advantage. To fully elucidate the behavior of ECs in a tumor microenvironment, high …

Tumor angiogenesis is important for the progression of cancer and is orchestrated by
various factors associated with tumor vessels, tumor cells, and stromal cells. Angiogenic …

Background: Vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (ANGPT2)
are key mediators in angiogenesis. The expression and clinical significance of VEGFA and …

Metastasis is the primary cause of cancer-related mortality. Tumor cell interactions with cells
of the vessel wall are decisive and potentially rate-limiting for metastasis. The molecular …